Loading clinical trials...

A Comparative Trial of TMS Approaches to Treating Depression | Clinical Trials | Clareo Health

WITHDRAWNPHASE4

A Comparative Trial of TMS Approaches to Treating Depression

NCT01906905•The University of New South Wales

Summary

Trancranial Magnetic Stimulation (TMS) is a non-drug and non-invasive treatment for depression and has been investigated for the treatment of psychiatric illness for over 15 years. There is now established evidence indicating TMS is an effective treatment for depression. However, the effectiveness of TMS varies between people, thus requiring further research to investigate its optimal application. Investigators want to compare the effectiveness of different forms of TMS, given with differing stimulation settings to the right or left side of the brain that has been associated with depression. This could potentially help clinicians in the future to improve the prescription of TMS as a treatment for depression.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years.
•2. DSM-IV diagnosis of current Major Depressive Episode.
•3. MADRS score of 20 or more.
•4. Able to give informed consent.

Exclusion Criteria

•1. DSM-IV psychotic disorder.
•2. Drug or alcohol abuse or dependence (preceding 3 months).
•3. Inadequate response to ECT (current episode of depression).
•4. Rapid clinical response required, e.g. high suicide risk.
•5. Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.
•6. Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.
•7. Pregnancy.

Locations (1)

Black Dog Institute, University of New South Wales

Sydney, New South Wales, Australia

Key Dates

Start Date

June 1, 2013

Primary Completion Date

December 1, 2013

Completion Date

December 1, 2013

Last Updated

April 3, 2023

Conditions

Depression

Interventions

Transcranial Magnetic Stimulation

DEVICE

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 3, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Comparative Trial of TMS Approaches to Treating Depression

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures